Nothing Special   »   [go: up one dir, main page]

MX2010010393A - Uso de la catepsina c. - Google Patents

Uso de la catepsina c.

Info

Publication number
MX2010010393A
MX2010010393A MX2010010393A MX2010010393A MX2010010393A MX 2010010393 A MX2010010393 A MX 2010010393A MX 2010010393 A MX2010010393 A MX 2010010393A MX 2010010393 A MX2010010393 A MX 2010010393A MX 2010010393 A MX2010010393 A MX 2010010393A
Authority
MX
Mexico
Prior art keywords
cathepsin
pain
aspects
treatment
present
Prior art date
Application number
MX2010010393A
Other languages
English (en)
Inventor
Martin Michaelis
Mathias Gebauer
Danping Ding-Pfennigdorff
Anke M Schulte
Christiane Metz-Weidmann
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2010010393A publication Critical patent/MX2010010393A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente invención se refiere al uso de Catepsina C. Otros aspectos de la invención se refieren a métodos para investigar fármacos, para diagnosticar susceptibilidad al dolor y para el tratamiento del dolor.
MX2010010393A 2008-03-26 2009-03-21 Uso de la catepsina c. MX2010010393A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290285A EP2105742A1 (en) 2008-03-26 2008-03-26 Use of cathepsin C
PCT/EP2009/002091 WO2009118137A1 (en) 2008-03-26 2009-03-21 Use of cathepsin c

Publications (1)

Publication Number Publication Date
MX2010010393A true MX2010010393A (es) 2010-10-20

Family

ID=39720231

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010393A MX2010010393A (es) 2008-03-26 2009-03-21 Uso de la catepsina c.

Country Status (15)

Country Link
US (1) US8349567B2 (es)
EP (2) EP2105742A1 (es)
JP (1) JP5748652B2 (es)
KR (1) KR101621273B1 (es)
CN (1) CN102150046B (es)
AR (1) AR071034A1 (es)
AU (1) AU2009228611B2 (es)
BR (1) BRPI0909223A2 (es)
CA (1) CA2719062A1 (es)
HK (1) HK1160925A1 (es)
IL (1) IL208236A (es)
MX (1) MX2010010393A (es)
MY (1) MY155340A (es)
TW (1) TWI510784B (es)
WO (1) WO2009118137A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2293072A1 (en) * 2009-08-31 2011-03-09 Sanofi-Aventis Use of cathepsin H
EP2547789B1 (en) * 2010-03-18 2015-07-22 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
EP2390349A1 (en) * 2010-05-25 2011-11-30 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
EP2390348A1 (en) * 2010-05-25 2011-11-30 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
KR101920187B1 (ko) 2010-07-07 2018-11-19 다이이찌 산쿄 가부시키가이샤 외래 유전자 발현 증강 활성을 갖는 ｄｎａ 요소
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
WO2012168453A1 (en) * 2011-06-10 2012-12-13 Sanofi Methods and uses relating to the diagnosis or prognosis of pain-related tissue states or pain-related diseases such as pain
CN111820188B (zh) * 2020-08-04 2021-10-29 中山大学附属第一医院 一种类哮喘慢阻肺重叠气道炎症小鼠模型的建立方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
JP4086317B2 (ja) 1996-03-25 2008-05-14 エルティエス ローマン テラピー―ズュステーメ アーゲー 塗布領域の厚さが薄く柔軟性が高い経皮治療システムおよびその製造方法
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
WO2004077053A1 (en) * 2003-02-25 2004-09-10 Biofrontera Pharmaceuticals Gmbh Cathepsin y for the treatment of pain
US7456027B2 (en) * 2004-04-15 2008-11-25 University Of Florida Research Foundation, Inc. Proteolytic biomarkers for traumatic injury to the nervous system
WO2005106012A2 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
EP1595945A1 (en) * 2004-05-14 2005-11-16 Boehringer Ingelheim International GmbH Screening method for identifying compounds that have the ability to inhibit the activity of Myc
US20080311036A1 (en) * 2005-05-11 2008-12-18 University Of Florida Research Foundation, Inc. Imaging of Neural and Organ Injury or Damage
GB0521512D0 (en) * 2005-10-21 2005-11-30 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
IL208236A (en) 2014-06-30
BRPI0909223A2 (pt) 2015-12-01
AU2009228611B2 (en) 2014-03-20
JP5748652B2 (ja) 2015-07-15
IL208236A0 (en) 2010-12-30
HK1160925A1 (zh) 2012-08-17
EP2260306B1 (en) 2014-07-16
CN102150046A (zh) 2011-08-10
KR20100128298A (ko) 2010-12-07
KR101621273B1 (ko) 2016-05-16
TW201000905A (en) 2010-01-01
EP2260306A1 (en) 2010-12-15
CA2719062A1 (en) 2009-10-01
CN102150046B (zh) 2016-01-06
MY155340A (en) 2015-10-15
US20110091888A1 (en) 2011-04-21
TWI510784B (zh) 2015-12-01
JP2011526143A (ja) 2011-10-06
WO2009118137A1 (en) 2009-10-01
EP2105742A1 (en) 2009-09-30
AR071034A1 (es) 2010-05-19
AU2009228611A1 (en) 2009-10-01
US8349567B2 (en) 2013-01-08

Similar Documents

Publication Publication Date Title
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX355543B (es) Macrociclos peptidomiméticos.
MY155340A (en) Use of cathepsin c
WO2010017515A3 (en) Breast cancer specific markers and methods of use
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
MX346450B (es) Composiciones y métodos para el tratamiento de la enfermedad celíaca.
EP2179037A4 (en) DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
EA201171367A1 (ru) Винилиндазолильные соединения
EP2260109A4 (en) METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR DIAGNOSING, PROGNOSING AND TREATING PROSTATE-RELATED DISORDERS
WO2009026657A8 (en) Flavonoid ppar agonists
MX2010006823A (es) Metodos para el tratamiento de la gota.
TNSN08400A1 (en) Organic compounds and their uses
EP2609220A4 (en) ASSOCIATION OF RARE RECURRENT GENETIC VARIATIONS WITH HYPERACTIVITY (ADHD) ATTENTION DEFICIT DISORDER AND ASSOCIATED METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF ADHD
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
IL204584A0 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
ZA201007005B (en) Methods of diagnosing, preventing and treating bone mass diseases
HK1150401A1 (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
MX2009009693A (es) Metodos para activar irs-1 y akt.

Legal Events

Date Code Title Description
FG Grant or registration